Ambroxol to Slow Progression in Parkinson Disease

This is a UK only clinical trial in patients with Parkinson's disease (PD) of a drug called ambroxol hydrochloride, which is an already licensed drug for the treatment of respiratory conditions (such as a common cold) in many European countries. The aim of this trial is to find out whether ambroxol hydrochloride can slow down the progression of Parkinson's disease and to evaluate it's safety and tolerability.

NCT Number	NCT05778617
Lead Sponsor	University College, London
Conditions	Parkinson Disease
Enrollment	330 participants
Start Date	2025-02-25
Primary Completion	2029-02 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2025-05-01